The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals.

Here's where Dr. David Eifrig says to move your money immediately.

Jaume Pons Biography and Net Worth

CEO of ALX Oncology

Dr. Pons has served as our President, Chief Executive Officer and a member of our board of directors since April 2015. He has also served as a Scientific Advisor at Lightstone Ventures, a venture capital fund, since January 2019 and as a Venture Partner at venBio Partners, a venture capital firm, since January 2017. Prior to joining us, Dr. Pons was with Pfizer, Inc., a biopharmaceutical company, where he served as Senior Vice President and a member of the Pfizer Worldwide Research and Development Leadership Team and Chief Technology Officer for Pfizer Biotherapeutics from September 2009 to February 2015. From October 2007 to February 2015, he served as Chief Scientific Officer at Rinat Neuroscience Corporation, a subsidiary of Pfizer. Dr. Pons holds a B.S. in Biochemistry from Autonomous University of Barcelona and an M.S. in Biotechnology and a Ph.D. in Molecular and Cell Biology from the Institute on Fundamental Biology, Barcelona (Autonomous University of Barcelona).

What is Jaume Pons' net worth?: The estimated net worth of Jaume Pons is at least $9.99 million as of April 16th, 2024. Dr. Pons owns 604,205 shares of ALX Oncology stock worth more than $9,993,551 as of April 26th. This net worth evaluation does not reflect any other assets that Dr. Pons may own. Additionally, Dr. Pons receives an annual salary of $856,290.00 as CEO at ALX Oncology. Learn More about Jaume Pons' net worth.
How old is Jaume Pons?: Dr. Pons is currently 57 years old. There are 5 older executives and no younger executives at ALX Oncology. Learn More on Jaume Pons' age.
What is Jaume Pons' salary?: As the CEO of ALX Oncology Holdings Inc., Dr. Pons earns $856,290.00 per year. Learn More on Jaume Pons' salary.
How do I contact Jaume Pons?: The corporate mailing address for Dr. Pons and other ALX Oncology executives is 866 MALCOLM ROAD SUITE 100, BURLINGAME CA, 94010. ALX Oncology can also be reached via phone at 650-466-7125 and via email at [email protected]. Learn More on Jaume Pons' contact information.
Has Jaume Pons been buying or selling shares of ALX Oncology?: During the past quarter, Jaume Pons has sold $933,000.00 in ALX Oncology stock. Most recently, Jaume Pons sold 50,000 shares of the business's stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $14.20, for a transaction totalling $710,000.00. Following the completion of the sale, the insider now directly owns 604,205 shares of the company's stock, valued at $8,579,711. Learn More on Jaume Pons' trading history.
Who are ALX Oncology's active insiders?: ALX Oncology's insider roster includes Peter Garcia (CFO), Jason Lettmann (Director), Jaume Pons (CEO), and Sophia Randolph (Insider). Learn More on ALX Oncology's active insiders.
Are insiders buying or selling shares of ALX Oncology?: In the last twelve months, ALX Oncology insiders bought shares 1 times. They purchased a total of 4,400 shares worth more than $49,764.00. In the last twelve months, insiders at the sold shares 8 times. They sold a total of 86,228 shares worth more than $1,063,099.04. The most recent insider tranaction occured on April, 16th when insider Jaume Pons sold 50,000 shares worth more than $710,000.00. Insiders at ALX Oncology own 50.3% of the company. Learn More about insider trades at ALX Oncology.
Information on this page was last updated on 4/16/2024.

Jaume Pons Insider Trading History at ALX Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/16/2024	Sell	50,000	$14.20	$710,000.00	604,205
4/4/2024	Sell	20,000	$11.15	$223,000.00	628,359
6/30/2023	Sell	3,208	$7.34	$23,546.72	536,538
10/19/2021	Sell	16,700	$54.29	$906,643.00
9/20/2021	Sell	16,700	$74.38	$1,242,146.00
8/19/2021	Sell	16,700	$61.28	$1,023,376.00
7/19/2021	Sell	16,700	$54.57	$911,319.00	509,946
6/21/2021	Sell	16,700	$58.59	$978,453.00	521,599
5/19/2021	Sell	16,700	$55.71	$930,357.00	544,146
4/19/2021	Sell	16,700	$57.63	$962,421.00	556,016
3/22/2021	Sell	16,700	$68.49	$1,143,783.00	568,046

Jaume Pons Buying and Selling Activity at ALX Oncology

ALX Oncology Company Overview

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Today's Range

Now: $16.86

$16.54

$17.37

50 Day Range

MA: $13.63

$10.72

$16.87

2 Week Range

Now: $16.86

$3.94

$17.42

Volume

466,719 shs

Average Volume

434,870 shs

Market Capitalization

$843 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Move Your Money Before May 22

From Stansberry Research | Ad

Here's where Dr. David Eifrig says to move your money immediately.

Jaume Pons Biography and Net Worth

What is Jaume Pons' net worth?

How old is Jaume Pons?

What is Jaume Pons' salary?

How do I contact Jaume Pons?

Has Jaume Pons been buying or selling shares of ALX Oncology?

Who are ALX Oncology's active insiders?

Are insiders buying or selling shares of ALX Oncology?